If you have wet age-related macular degeneration (wet AMD) or another disease of the retina, your doctor may recommend treatment with an anti-VEGF drug. VEGF, or vascular endothelial growth factor, is ...

Age-related macular degeneration is the leading cause of vision loss in those who are age 50 or older. In fact, almost 20 million people in the U.S. have some type of age-related macular degeneration, ...

One of the two most common drugs used to treat age-related macular degeneration (AMD) appears better than the other, a new, small study suggests. Among 106 patients with "wet" age-related macular ...

Wet macular degeneration, also called “advanced neovascular macular degeneration,” is less common but more severe. It affects 10–15% of people with macular degeneration. It occurs when abnormal blood ...

People with a condition called wet age-related macular degeneration (AMD) often receive eye injections. These eye injections can help to improve vision and also stop the damage that causes vision to ...

CHICAGO — The number of injections required for the successful treatment of neovascular age-related macular degeneration could be reduced considerably with experimental therapies, new research shows.

Larry Hoffheimer watched helplessly as his mother, Florence, went from doctor to doctor seeking better glasses more than 20 years ago. Getting a diagnosis of macular degeneration didn’t resolve the ...

First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period Monthly dosing ...

The FINANCIAL — Bayer HealthCare’s collaboration partner, Regeneron Pharmaceuticals has received approval from the U.S. Food and Drug Administration for EYLEA Injection, known in the scientific ...

Gene therapy has the promise of being one and done, but it isn’t always that way for all patients, which leaves questions about where these therapies fit in the commercial landscape, said Charles C.

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Patients with ...

The research team is now monitoring 12 more participants who received higher doses of 150,000 and 250,000 cells. If no safety ...